MC Services AG’s Post

🌟 MC Services is proud to be a media partner for #LSIEurope24! 🌟   Join us from September 16–20, 2024, at the stunning Penha Longa Ritz-Carlton in Sintra, Portugal, for the 2024 LSI Europe Medtech Summit—one of the premier partnering events in the Medtech and Healthtech industries. Hosted by LSI, this year’s summit will bring together nearly 1,000 top executives from emerging companies, venture capital firms, private equity, family offices, global strategics, and leading service providers. Don’t miss the opportunity to network, build partnerships and gain insights into the future of Medtech innovation.   📣 Featured sessions include leading experts like Todd Brinton, MD and Dr. Josh Makower covering topics such as "Unlocking Disruptive Innovation" and "The EU AI Act".   Connect with Brittney Sojeva at the press lounge or schedule a meeting on-site to explore how we provide comprehensive support for Life Science companies in Corporate Communications and Investor Relations.   Partnering is open: https://lnkd.in/e_zXjs5J    #LSIEurope24 #Medtech #Healthtech #Innovation #Networking #Investors

🎉 We are delighted to share that Katja Arnold, our esteemed Managing Director & Partner, has been elevated to our Management Board! Katja's journey with us, which began in 2013, builds on her many years of leadership at the Munich office and exemplifies her dedication and expertise in financial and strategic communications. Her appointment is a milestone for MC Services, as she has over 25 years of experience with companies in the healthcare sector, including biotechnology, medical technology, and diagnostics, as well as for venture capital firms, which she brings to our board. Katja's leadership and vision is invaluable as we continue to grow and innovate. Join us in congratulating Katja on this well-deserved achievement! 

It has been a landmark year for the TCR-T field, with the FDA granting approval in August for the very first TCR-engineered T cell therapy, as reported by Asher Mullard in Nature Magazine by Nature Portfolio. Want to explore more about this key development and its future potential? 🎧 Dive into the latest episode of S&S, where Cormac Sheridan interviews Medigene’s CEO, Selwyn Ho, for expert insights: https://lnkd.in/eVfycfpB #TCRT #celltherapy #immunotherapy

#BIOEurope is Europe's premier partnering event for the life sciences industry, bringing together thousands of executives from biotechnology, pharmaceutical, and finance companies. This event offers an unmatched opportunity to network, forge partnerships, and discover the latest innovations in #biotech. A key highlight of this year’s conference is Merck Group’s EMEA Advance Biotech Grant Program, designed to help emerging biotech companies accelerate their journey to commercialization! Is your company developing breakthrough biologics or pioneering new therapies? Then, this is a valuable platform to kickstart your next big step in innovation. Five selected companies will have the chance to showcase their work to industry leaders and Merck’s Grant representatives, gaining invaluable visibility and support. The program offers access to advanced bioprocessing technologies and expert consultation from M Ventures —resources that can elevate your biotech advancement. 📅 With the application deadline on September 9, 2024, now is the time to step up and secure your spot among industry frontrunners. Don’t miss this chance—apply now and make your mark at BIO-Europe! https://lnkd.in/dxVe5ctU 🔬💡 #Innovation #Healthcare #Biotechnology #Merck

𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝘄𝗶𝘁𝗵 𝗔𝗜: 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗼𝗻 𝗢𝘂𝗿 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀 We’re thrilled to see our clients Volta Medical and Molecular Health featured in the latest FOCUS Magazin article by Kurt-Martin Mayer, exploring how artificial intelligence is revolutionizing the medical field. 🔍 Volta Medical, under the visionary leadership of CEO Théophile Mohr Durdez, is prominently highlighted for their transformative AI-driven software that assists electrophysiologists, like Dr. Isabel Deisenhofer at the German Heart Center, in real-time to assess dispersed electrograms during catheter ablation with remarkable precision. Their technology, based on extensive data derived from acute and long-term outcomes from expert EPs, has boosted success rates significantly—showcasing the potential of AI to enhance patient outcomes. 🧬 Molecular Health, guided by the strategic foresight of CEO Friedrich von Bohlen, is also recognized in the article with its data-driven software technology and AI solutions, transforming biomedical knowledge into actionable insights for pharma and genetic analysis. Check out the full article in FOCUS Issue 32/2024 for an in-depth look at these advancements. #Technology #Innovation #Health #AI #DigitalHealth

On the passing of our longtime colleague and dear friend, Andreas Burckhardt We are deeply saddened by the loss of our colleague and friend, Andreas Burckhardt, who had been a valuable member of our management team and partner at MC Services AG since 2013. As head of our corporate broking business, Andreas successfully supported our clients on numerous roadshows and in many transactions and served as a trusted advisor and partner for all topics related to corporate financing. With his many years of experience in international investment banking and his great expertise in the healthcare and life sciences sector, Andreas made an enormous contribution to the development of MC Services and was highly respected throughout the investment community. 

Congratulations to Affluent Medical on this significant milestone! The signing of agreements with €15 million in upfront payments is a strong endorsement of their innovative mitral valve technologies. This achievement reflects the #dedication, #expertise and #perseverance of the team in advancing medical solutions that improve patients' quality of life worldwide. Well deserved!

👏 Congratulations to Olivier Taelman and the entire Nyxoah team who just inked a €37.5 million loan facility agreement with the European Investment Bank (EIB) - We are thrilled to see your hard work being recognized! Nyxoah develops and commercializes an innovative patient-centric neuromodulation solution for the treatment of obstructive sleep apnea, the most common breathing disorder during sleep worldwide. Their vision is to enable OSA patients to enjoy restful nights and live their life to its fullest. 🌙 Curious about what Nyxoah intends to use the financing for? Find out directly from the Company’s CFO, Loïc Moreau, as he lays out their plans and offers an outlook on the upcoming milestones in Nyxoah’s growth path: https://lnkd.in/e7cHsvmQ

BioM Biotech Cluster Development GmbH’s highly anticipated event #BayOConnect - Forum for Biotech & LifeScience is coming up in Munich for the next two days! On July 2 the focus will be how to “Connect to Investment”, while on July 3, the spotlight will be on one of the biggest trends in Life Sciences exploring how to “Connect to AI”.   You won’t want to miss out on these program highlights featuring our clients:   “Risk and Reward - Comparative Strategies in Biotech Funding” June 2, 1:30 PM, with Olivier Litzka of Andera Partners   “Spotlight: Are we ready for AI?” June 3, 2:10 PM, with Dr. Friedrich von Bohlen of Molecular Health   Also, make sure to join the Pitch Session on June 2 at 2:30 PM, and connect with other like-minded, innovative start-ups such as AATec Medical and Mallia Therapeutics.   We can also recommend checking out the latest scientific posters during the breaks, including:    Secarna Pharmaceuticals: “Leading independent European antisense drug discovery & development company”  AATec Medical: “Novel Therapeutics for Globally Increasing Respiratory Diseases”   Schedule a meeting with our MC Services colleagues Eva Bauer, Dr. Cora Kaiser, Regina Lutz and Philipp Streng to find out more about how we support Life Science companies with expert Corporate Communications and Investor Relations insights: https://lnkd.in/d6ikVBPw   You can find the full agenda and the latest news from BayOConnect here: https://lnkd.in/dGMqmzYS #BayOConnect #LifeSciences #CorporateCommunications #InvestorRelations #MCServices #Networking #Biotech #Startup #Bayern #BioM 

Did you already register for Newron's 2024 Investor Day on their lead program evenamide for schizophrenia? You can also join via webcast - see below!